Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
|
Circulation
|
2009
|
35.24
|
2
|
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
|
N Engl J Med
|
2005
|
15.18
|
3
|
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
|
N Engl J Med
|
2007
|
6.31
|
4
|
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
|
Lancet
|
2006
|
5.67
|
5
|
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.
|
J Clin Invest
|
2006
|
3.48
|
6
|
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
|
Diabetes Care
|
2006
|
3.37
|
7
|
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.
|
J Biol Chem
|
2006
|
2.38
|
8
|
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
|
Diabetes
|
2005
|
2.32
|
9
|
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
|
Circ Res
|
2004
|
2.16
|
10
|
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
|
J Am Coll Cardiol
|
2006
|
2.15
|
11
|
Increased ABCA1 activity protects against atherosclerosis.
|
J Clin Invest
|
2002
|
2.13
|
12
|
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study.
|
Atherosclerosis
|
2003
|
2.02
|
13
|
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.
|
Arterioscler Thromb Vasc Biol
|
2003
|
1.99
|
14
|
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis.
|
Circulation
|
2004
|
1.98
|
15
|
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
|
J Biol Chem
|
2005
|
1.85
|
16
|
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.
|
J Clin Invest
|
2002
|
1.80
|
17
|
Safety issues and prospects for future generations of PPAR modulators.
|
Biochim Biophys Acta
|
2007
|
1.79
|
18
|
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.
|
J Neurosci
|
2003
|
1.78
|
19
|
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation.
|
J Biol Chem
|
2003
|
1.76
|
20
|
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.
|
Circ Res
|
2004
|
1.72
|
21
|
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription.
|
J Lipid Res
|
2002
|
1.71
|
22
|
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.68
|
23
|
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element.
|
Mol Endocrinol
|
2002
|
1.63
|
24
|
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha.
|
Arterioscler Thromb Vasc Biol
|
2005
|
1.63
|
25
|
Glucose regulates the expression of the farnesoid X receptor in liver.
|
Diabetes
|
2004
|
1.63
|
26
|
Atherogenic lipoprotein particles in atherosclerosis.
|
Circulation
|
2004
|
1.63
|
27
|
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
|
Mol Endocrinol
|
2003
|
1.60
|
28
|
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
|
J Clin Invest
|
2005
|
1.58
|
29
|
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages.
|
Atherosclerosis
|
2006
|
1.54
|
30
|
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
|
Gastroenterology
|
2003
|
1.54
|
31
|
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.
|
Biochem Biophys Res Commun
|
2004
|
1.53
|
32
|
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.48
|
33
|
Implications of emerging risk factors for therapeutic intervention.
|
Nutr Metab Cardiovasc Dis
|
2005
|
1.43
|
34
|
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.
|
Atherosclerosis
|
2002
|
1.41
|
35
|
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
|
Nat Clin Pract Endocrinol Metab
|
2007
|
1.41
|
36
|
Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.
|
J Clin Invest
|
2005
|
1.37
|
37
|
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.
|
J Biol Chem
|
2002
|
1.36
|
38
|
Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.
|
Arterioscler Thromb Vasc Biol
|
2009
|
1.36
|
39
|
Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.
|
J Biol Chem
|
2003
|
1.31
|
40
|
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
|
Arterioscler Thromb Vasc Biol
|
2006
|
1.26
|
41
|
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
|
Curr Med Res Opin
|
2004
|
1.25
|
42
|
The role of PPARs in atherosclerosis.
|
Trends Mol Med
|
2002
|
1.22
|
43
|
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.
|
J Biol Chem
|
2002
|
1.22
|
44
|
Transient impairment of the adaptive response to fasting in FXR-deficient mice.
|
FEBS Lett
|
2005
|
1.21
|
45
|
Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo.
|
Circulation
|
2006
|
1.20
|
46
|
Combination lipid therapy in type 2 diabetes.
|
N Engl J Med
|
2010
|
1.20
|
47
|
Plasma cystatin-C and development of coronary heart disease: The PRIME Study.
|
Atherosclerosis
|
2005
|
1.19
|
48
|
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.16
|
49
|
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
|
Curr Opin Pharmacol
|
2006
|
1.16
|
50
|
Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha.
|
J Biol Chem
|
2002
|
1.14
|
51
|
Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.
|
Circ Res
|
2006
|
1.13
|
52
|
Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.
|
Mol Endocrinol
|
2008
|
1.12
|
53
|
The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages.
|
Mol Endocrinol
|
2008
|
1.11
|
54
|
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity.
|
Gastroenterology
|
2003
|
1.11
|
55
|
PPARs: transcription factors controlling lipid and lipoprotein metabolism.
|
Ann N Y Acad Sci
|
2002
|
1.10
|
56
|
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.
|
Biochem Biophys Res Commun
|
2006
|
1.09
|
57
|
Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
|
Arterioscler Thromb Vasc Biol
|
2002
|
1.09
|
58
|
DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha.
|
Mol Endocrinol
|
2002
|
1.07
|
59
|
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha.
|
Mol Endocrinol
|
2004
|
1.07
|
60
|
Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation.
|
FEBS J
|
2006
|
1.06
|
61
|
Apolipoprotein A-II, HDL metabolism and atherosclerosis.
|
Atherosclerosis
|
2002
|
1.06
|
62
|
The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.
|
J Biol Chem
|
2003
|
1.05
|
63
|
Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages.
|
Circ Res
|
2007
|
1.05
|
64
|
The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
|
FEBS Lett
|
2004
|
1.04
|
65
|
Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
|
Curr Opin Pharmacol
|
2005
|
1.03
|
66
|
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.
|
Mol Cell Biol
|
2005
|
1.02
|
67
|
Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
|
Diabetes
|
2006
|
1.02
|
68
|
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.
|
Atherosclerosis
|
2004
|
1.01
|
69
|
Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.
|
J Biol Chem
|
2003
|
1.00
|
70
|
Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms.
|
J Cardiovasc Pharmacol
|
2006
|
0.99
|
71
|
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
|
Ann Med
|
2006
|
0.99
|
72
|
Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function.
|
Curr Opin Lipidol
|
2003
|
0.98
|
73
|
Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha.
|
Mol Pharmacol
|
2004
|
0.94
|
74
|
Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice.
|
Arterioscler Thromb Vasc Biol
|
2004
|
0.92
|
75
|
Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI.
|
J Biol Chem
|
2005
|
0.92
|
76
|
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
|
Arterioscler Thromb Vasc Biol
|
2006
|
0.92
|
77
|
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.
|
Expert Opin Emerg Drugs
|
2006
|
0.92
|
78
|
The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c.
|
J Biol Chem
|
2004
|
0.92
|
79
|
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
|
Atherosclerosis
|
2004
|
0.91
|
80
|
[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
|
J Soc Biol
|
2002
|
0.91
|
81
|
FXR-deficiency confers increased susceptibility to torpor.
|
FEBS Lett
|
2007
|
0.91
|
82
|
Different ways to regulate the PPARalpha stability.
|
Biochem Biophys Res Commun
|
2004
|
0.91
|
83
|
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
|
Trends Endocrinol Metab
|
2004
|
0.88
|
84
|
Postprandial leptin response to carbohydrate and fat meals in obese women.
|
J Am Coll Nutr
|
2003
|
0.88
|
85
|
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome.
|
Clin Chem Lab Med
|
2007
|
0.88
|
86
|
Farnesoid X receptor represses hepatic lipase gene expression.
|
J Lipid Res
|
2004
|
0.87
|
87
|
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
|
Circ Res
|
2008
|
0.87
|
88
|
The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
|
J Cardiovasc Pharmacol
|
2007
|
0.87
|
89
|
Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line.
|
Biochim Biophys Acta
|
2003
|
0.87
|
90
|
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
|
Diabetologia
|
2005
|
0.86
|
91
|
Potential regulatory role of the farnesoid X receptor in the metabolic syndrome.
|
Biochimie
|
2005
|
0.86
|
92
|
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.
|
Ther Adv Chronic Dis
|
2011
|
0.85
|
93
|
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
|
J Med Chem
|
2005
|
0.85
|
94
|
Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles.
|
Atherosclerosis
|
2003
|
0.85
|
95
|
Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages.
|
J Biol Chem
|
2005
|
0.85
|
96
|
Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.83
|
97
|
Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.
|
Biochem Biophys Res Commun
|
2002
|
0.82
|
98
|
Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.
|
Trends Pharmacol Sci
|
2003
|
0.82
|
99
|
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
|
Arch Med Res
|
2004
|
0.82
|
100
|
Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells.
|
Cell Res
|
2006
|
0.82
|
101
|
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
|
J Cardiovasc Pharmacol
|
2005
|
0.82
|
102
|
Expression and secretion of human apolipoprotein A-I in the heart.
|
FEBS Lett
|
2004
|
0.82
|
103
|
Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development.
|
J Vasc Res
|
2006
|
0.81
|
104
|
Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis.
|
Am J Clin Nutr
|
2005
|
0.81
|
105
|
The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity.
|
Diabetes Care
|
2007
|
0.81
|
106
|
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.
|
J Cardiovasc Pharmacol
|
2004
|
0.80
|
107
|
Lipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins.
|
J Biol Chem
|
2002
|
0.80
|
108
|
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
|
Curr Med Res Opin
|
2004
|
0.80
|
109
|
PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
|
Semin Arthritis Rheum
|
2007
|
0.80
|
110
|
Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis.
|
J Lipid Res
|
2005
|
0.80
|
111
|
Enhanced cholesterol efflux promotion in well-trained soccer players.
|
Metabolism
|
2004
|
0.80
|
112
|
Glucose regulates the expression of the apolipoprotein A5 gene.
|
J Mol Biol
|
2008
|
0.79
|
113
|
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
|
Bioorg Med Chem Lett
|
2007
|
0.78
|
114
|
Liver X receptors: new players in atherogenesis?
|
Curr Opin Lipidol
|
2003
|
0.78
|
115
|
Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity.
|
Planta Med
|
2003
|
0.78
|
116
|
[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].
|
Endocrinol Nutr
|
2011
|
0.78
|
117
|
Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency.
|
J Lipid Res
|
2006
|
0.78
|
118
|
Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
|
Clin Chim Acta
|
2006
|
0.77
|
119
|
SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R.
|
Biochim Biophys Acta
|
2003
|
0.77
|
120
|
Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates.
|
Biochim Biophys Acta
|
2002
|
0.77
|
121
|
[Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
|
Med Sci (Paris)
|
2003
|
0.77
|
122
|
Natural phenylpropanoids inhibit lipoprotein-induced endothelin-1 secretion by endothelial cells.
|
J Pharm Pharmacol
|
2004
|
0.77
|
123
|
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.
|
Clin Sci (Lond)
|
2002
|
0.76
|
124
|
[PPAR gamma: a major nuclear receptor in adipogenesis].
|
Med Sci (Paris)
|
2003
|
0.76
|
125
|
The plasma and lipoprotein triglyceride postprandial response to a carbohydrate tolerance test differs in lean and massively obese normolipidemic women.
|
J Nutr
|
2002
|
0.76
|
126
|
Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis.
|
Drug News Perspect
|
2006
|
0.76
|
127
|
Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation.
|
J Pineal Res
|
2002
|
0.75
|
128
|
Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine.
|
Cell Physiol Biochem
|
2009
|
0.75
|
129
|
Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.
|
Biochim Biophys Acta
|
2004
|
0.75
|
130
|
[4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs).
|
Chem Biodivers
|
2006
|
0.75
|
131
|
Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.
|
Front Biosci
|
2007
|
0.75
|